Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma.
The objective of this study was to determine if the nuclear DNA content could predict disease progression in patients with stage A or B prostatic cancer. The nuclear DNA content was determined by image analysis using Feulgen-stained nuclei in tissue sections of prostatic needle biopsies from 44 patients. The patients were followed for a mean of 69.5 months, during which 12 (17%) progressed to stage D2 disease (bone or soft tissue metastases). The average times to progression to stage D2 disease were 68 months for patients who initially had stage A2 disease, 47 months for stage B1 patients and 29 months for stage B2 patients. The DNA pattern was judged diploid or normal-range (Auer type I or II histogram) in 35 tumors (80%) and aneuploid (Auer type III or IV histogram) in 9 tumors (20%). Eight (89%) of 9 tumors with an aneuploid DNA pattern and 4 (11%) of 35 tumors with a normal-range or diploid DNA pattern progressed to stage D2 disease.
Department of Urology, Henry Ford Hospital, Detroit, Michigan.
J M
JM
Peters
B J
BJ
Miles
J J
JJ
Kubus
J D
JD
Crissman
D000230:Adenocarcinoma / Q000235:genetics*; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D004396:Coloring Agents; D004273:DNA, Neoplasm / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics*; D012394:Rosaniline Dyes; D013194:Staining and Labeling
D004396:Coloring Agents; D004273:DNA, Neoplasm; C007722:Feulgen stain; D012394:Rosaniline Dyes